Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001181431-11-018573
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-03-17 07:00:26
Reporting Period:
2011-02-21
Filing Date:
2011-03-17
Filing Date Changed:
2011-03-17
Accepted Time:
2011-03-17 08:00:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1103021 Biodelivery Sciences International Inc BDSI Pharmaceutical Preparations (2834) 352089858
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1301715 A Mark Sirgo C/o Biodelivery Sciences Intl, Inc.
801 Corporate Center Drive, Suite 210
Raleigh NC 27607
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-03-15 2,130 $3.30 829,162 No 4 P Direct
Common Stock Acquisiton 2011-03-15 900 $3.28 830,062 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option Acquisiton 2011-02-21 22,369 $0.00 22,369 $3.55
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
22,369 2021-02-25 No 4 A Direct
Footnotes
  1. One third of the options granted herein will vest and be exercisable on each of the following dates, February 25, 2012, February 25, 2013 and February 25, 2014, subject to the condition that the reporting person is employed by the Issuer on each of the respective dates.
  2. Not applicable. Such options were granted by Issuer's Board of Directors as compensation for serving as President and Chief Executive Officer.